Staidson (300204.SZ): Injection STSP-0601 included in priority review program.

Staidson (300204.SZ) announced that its subsidiary, Jiangsu Beijie Tai Biological Technology Co., Ltd. (hereinafter referred to as "Beijie Tai"), had its product STSP-0601 for injection included in the pre-priority review variety public notice list by the National Medical Products Administration Drug Evaluation Center on May 26, 2025. After the public notice period expires, according to the information publicly available on the website of the National Medical Products Administration Drug Evaluation Center, it was included in the priority review variety list on June 5, 2025, officially entering the priority review and approval process for drug market authorization.